Skip to content

CG Oncology CGON Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-4,239%+483pp-4,722.1%+3,563pp-8,285.3%+20,261pp-28,546.1%-8,244pp-20,302.3%-10,235pp
Net margin-3,682.6%+302pp-3,985%+2,983pp-6,968%+16,277pp-23,245.2%-7,300pp-15,945.2%-8,216pp
Returns
Return on equity-20.8%+0.9pp-21.7%
Return on invested capital-24.9%+6.8pp-31.7%
Efficiency
Asset turnover0.0×0.0×
Liquidity
Current ratio31.3×+6.7×24.6×+1.8×22.8×+0.6×22.2×-8.8×31×-4.3×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$12.92+32.7%$9.74+8.6%$8.96+1.9%$8.79-4.9%$9.25-21.2%
Valuation
Market capitalization$5.71B+70.6%$3.35B+9.1%$3.07B+56.2%$1.97B+5.4%$1.87B-14.5%
Price / sales1,126.9×+298×829×-584×1,412.7×-2,156×3,569.2×+750×2,819.6×+903×
Price / book5.2×+0.8×4.5×0.0×4.5×+1.5×2.9×+0.3×2.6×-0.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do CG Oncology's ratios come from?
Every ratio is computed from CG Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.